·Week of October 5-9, 2026

Clinical Trials Brief | October 12, 2026

This week: Kenya confirming the first imported Bundibugyo Ebola case as DRC cases pass 8,600, FDA setting out how it would design the first ibogaine trials, EMA making its pre-submission advice for EU clinical trial applications permanent, FDA telling a court its mifepristone safety review will finish in March, and argenx stopping its Phase 3 Sjögren's trial for futility.

Kenya confirms the first imported Bundibugyo Ebola case as DRC cases pass 8,600

What changed

On October 6, 2026, Kenya confirmed its first imported case of Bundibugyo virus disease. According to Kenyan government and WHO statements, the patient was a Kenyan citizen who had lived in the DRC, fell ill there and was treated at several facilities, then travelled by road to Kampala and flew to Nairobi on October 3. He was isolated in hospital and died on the night of October 5. Samples tested positive at the National Virology Reference Laboratory and KEMRI. Kenya notified WHO under the International Health Regulations and is the fourth country to confirm the disease in this outbreak, after the DRC, Uganda and France. Xinhua reported that authorities listed 28 contacts and were tracing 23 passengers and four crew from the flight. WHO said it advises against travel or trade restrictions on the DRC, Uganda or Kenya. ContagionLive reports that, through October 4, the DRC had recorded 8,603 confirmed cases, 4,148 deaths and 2,235 recoveries, a case fatality rate of 48.2%.

Why it matters

This brief has followed the Bundibugyo response since June, from the PARTNERS treatment trial to post-exposure prophylaxis and the Ervebo vaccine studies. A single imported case is not a Kenyan outbreak, and Kenya's government has stressed that. It is, however, a reminder that the outbreak has not been contained after five months, and that the trials now running in the DRC are the main route to evidence on any countermeasure. The case also shows how long travel chains through several countries can delay detection.

Takeaway

Sponsors and sites in East Africa should check that outbreak-response protocols, including screening of trial participants and staff with relevant travel history, are current. For the Bundibugyo trials, wider geographic spread would raise questions about adding sites and regulatory approvals outside the DRC. Pre-agreed regional reliance arrangements would make that faster.

Sources

This item is grounded in Kenya government and WHO statements of October 6-8, 2026, Xinhua reporting via Bernama, and ContagionLive's October 8 outbreak summary.

FDA sets out how it would design the first ibogaine trials, with a capped starting dose and in-hospital cardiac monitoring

What changed

On October 5, 2026, FDA published a request for information describing approaches it is considering for early-phase clinical trials of ibogaine and asking for public input. The RFI covers dose selection and escalation, care setting, safety monitoring, eligibility criteria, stopping rules and safety oversight. Applied Clinical Trials reports a proposed starting dose of no more than 10 mg/kg, and Reuters reports that, under the approaches outlined, participants would receive single, gradual doses and remain under continuous in-hospital heart monitoring for up to 36 hours. Comments are due November 20, 2026 (docket FDA-2026-N-10429). The RFI follows the April 2026 executive order on accelerating psychedelic research. HHS is prioritising adults with opioid use disorder and post-traumatic stress disorder, with early-phase trials funded through ARPA-H and the National Institute on Drug Abuse. Ibogaine is a Schedule I substance, so trials must also meet DEA requirements. FDA has previously warned of life-threatening heart rhythm problems and potential brain toxicity with ibogaine.

Why it matters

It is unusual for FDA to publish its draft thinking on a specific compound's first-in-human design and ask for comment before sponsors file. It follows the general psychedelic guidance finalised in July and the September public hearing on psychedelic medicine. CDER Director Michael Davis acknowledged both important scientific questions and serious safety concerns. The proposed design, with a capped starting dose, gradual escalation, prolonged cardiac telemetry and an inpatient setting, shows that the cardiac risk will drive operations: these will be resource-heavy trials that only sites with inpatient telemetry and controlled-substance handling can run.

Takeaway

Groups planning ibogaine or related studies should comment by November 20, especially on monitoring duration, eligibility exclusions for cardiac risk and stopping rules, since these will shape feasibility and cost. Sites should assess telemetry capacity and DEA Schedule I readiness now if they want to participate.

EMA makes its pre-submission advice for EU clinical trial applications permanent from January 2027

What changed

On October 8, 2026, EMA announced that its clinical trial applications advice pilot will become permanent, with technical and regulatory support for preparing clinical trial applications continuing from January 2027. The pre-CTA pilot, launched under ACT EU and coordinated by the Clinical Trials Coordination Group (CTCG) of Member States, gives sponsors consolidated technical and regulatory advice on a clinical trial application dossier before it is submitted in CTIS. When it was launched, EMA said its scope included regulatory questions such as low-intervention trial status and trials with decentralised elements or complex designs. A separate pilot ran alongside it, offering joint scientific advice from EMA's Scientific Advice Working Party and the CTCG on trial design and marketing authorisation requirements. The October announcement refers specifically to the CTA preparation support.

Why it matters

Under the Clinical Trials Regulation, the clock runs fast once an application is submitted, and requests for information from several Member States can be costly. Advance advice from the Member States that will actually assess the application is one of the few ways to reduce that risk. Making it permanent turns a pilot into a stable part of EU trial infrastructure, alongside FAST-EU and the CTIS changes planned under the Biotech Act.

Takeaway

Sponsors planning complex, decentralised or low-intervention multinational EU trials for 2027 should build a pre-CTA advice step into their start-up timelines. The advice is most useful when the questions are specific and the dossier is close to final.

Sources

This item is grounded in EMA's homepage announcement of October 8, 2026 and EMA and ACT EU pages describing the consolidated advice pilots.

FDA tells a federal court its mifepristone safety review will be completed in March

What changed

NBC News reported on October 7, 2026 that FDA told a federal court in Louisiana it expects to complete its safety review of mifepristone in March. A federal judge had ordered FDA to provide an update on the review as part of a lawsuit seeking to overturn the provision allowing mifepristone to be prescribed by telehealth and delivered by mail. According to NBC, HHS Secretary Robert F. Kennedy Jr. commissioned the review last year after a conservative think tank claimed to have found a higher rate of serious complications than FDA had reported. In May 2026, the Supreme Court issued an order preserving FDA's current REMS framework for mifepristone while litigation over the 2023 REMS changes continues.

Why it matters

This brief normally covers safety signals rather than litigation, but this is a post-marketing safety review of an approved medicine with a fixed completion date, and its methods will be closely examined. The review was prompted by an external analysis claiming a higher complication rate, not by a signal from FDA's own surveillance. How FDA weighs different data sources, including spontaneous reports, claims data, published studies and external analyses, and whether it publishes its methods, will matter well beyond this product. FDA commissioner nominee Heidi Overton said at her September hearing that she would not prejudge the review.

Takeaway

For pharmacovigilance professionals, the review is worth following as a case study in how a regulator handles an externally generated safety claim: what evidence threshold triggers label or REMS changes, and how transparent the methods are. We will report the outcome when it is published.

Sources

This item is grounded in NBC News reporting of October 7, 2026 and McDermott Will & Schulte's September 2026 client alert on the regulatory context.

argenx stops its Phase 3 Sjögren's trial for futility, its second efgartigimod programme ended by an IDMC in a year

What changed

On October 8, 2026, argenx announced that it will discontinue the Phase 3 UNITY study of subcutaneous efgartigimod (efgartigimod alfa and hyaluronidase-qvfc) in adults with moderate-to-severe Sjögren's disease. The decision followed a recommendation from an Independent Data Monitoring Committee to stop for futility after an interim analysis, which concluded the study could not meet its primary endpoint. Chemxplore reports that the primary endpoint was change from baseline in clinESSDAI at week 48. Safety was consistent with efgartigimod's established profile, with no new safety signals. UNITY was randomised 1:1, double-blind and placebo-controlled, with an open-label extension. According to Pharmacally, the study began in January 2025 with an estimated primary completion date of July 2027, and argenx had previously discontinued its UplighTED studies in thyroid eye disease in December 2025. argenx said it will analyse the full data after database lock. Chief Medical Officer Luc Truyen described Sjögren's as one of the most heterogeneous diseases in immunology.

Why it matters

Sjögren's has been a hard disease for drug development; in my reading, part of the problem is that systemic activity scores combine very different organ manifestations, which makes treatment effects hard to detect. Commentators noted that UNITY followed a much smaller positive Phase 2 study, a familiar pattern when early signals in heterogeneous diseases do not hold up at scale. For argenx, it is a second stop for futility in efgartigimod's expansion beyond its core indications, even as myasthenia gravis and CIDP continue to grow. The interim futility design worked as intended, ending the trial about nine months before its planned primary completion.

Takeaway

For autoimmune trials with composite activity endpoints, patient selection and enrichment strategy deserve as much attention as the drug. Sponsors in Sjögren's should look closely at the full UNITY data once released, especially which clinESSDAI domains moved and how the placebo arm behaved.

Clinical Trials Brief is an educational commentary archive, not a real-time news service. Confirmed facts are based on publicly cited sources where possible. Analytical comments, comparisons, and forward-looking views are personal interpretation unless otherwise stated.